Original ArticleEfficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL)
Key Words
Cited by (0)
Disclosure: Nicola Moore, MSc, is employed by and holds stock in F. Hoffman-La Roche. Martin Reck, MD, PhD, received consulting fees and speaking fees from AstraZeneca, Eli Lilly, F. Hoffman-La Roche, and Merck. Christian Manegold, MD, received consulting fees and speaking fees from F. Hoffman-La Roche. All other authors report no involvements that might raise the question of bias.
All authors made substantial contributions to the conception and design, acquisition of data, or analysis and interpretation of data, critically reviewed all drafts of the manuscript, and approved the final manuscript for submission. The academic authors vouch for the veracity and completeness of the data and data analysis. The sponsor did not influence the content of the manuscript or place any restrictions on the academic authors regarding statements made in the final manuscript. The authors did not receive financial compensation for authoring the manuscript.